Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

To join this study, people generally need to be 18 years or older and have a confirmed diagnosis of advanced stomach cancer or cancer where the food pipe joins the stomach that cannot be removed by surgery. Critically, your cancer must have come back or worsened after previous platinum-based chemotherapy treatments.

You also need to be well enough to take part, meaning you can mostly look after yourself. Your body's organs, such as your liver, kidneys, and blood, need to be working within certain healthy ranges. The researchers will also need to review a sample of your tumour tissue to understand specific features of your cancer.

There are also reasons why someone might not be able to join. For example, if you are currently in another clinical study, if you've recently had other cancer treatments (within the last two weeks before this study starts), or if you have certain other serious health conditions, you might not be eligible. The study team will discuss all these details with you.

If you decide to take part in this study, you would first go through a screening process to check if you meet all the requirements. This involves various tests and checks similar to what you might have for regular cancer care. Once you're in the study, you would receive either one of the two treatment combinations (FOLFIRI with Durvalumab, or FOLFIRI with Durvalumab and Tremelimumab).

The treatments would be given in cycles, typically involving visits to the clinic for infusions. You would have regular check-ups, blood tests, and scans (like CT scans) to monitor your health, how you're responding to the treatment, and to look for any side effects. The exact number of visits and tests would be explained by the study team, but generally, studies like this involve frequent hospital visits during the treatment phase and then follow-up appointments after treatment if it ends. The total duration of your participation would depend on how your body responds to the treatment.